The therascreen BRAF RGQ PCR Kit is an in vitro diagnostic test for the detection of five somatic mutations found in the BRAF gene and provides qualitative assessment of mutation status. DNA will be extracted from formalin fixed paraffin-embedded (FFPE) tumor tissue and tested using real-time polymerase chain reaction (PCR) on Rotor-Gene Q MDx instruments. 

The therascreen BRAF RGQ PCR Kit is intended to aid the clinician in identifying cancer patients who
may benefit from BRAF targeted therapy, such as vemurafenib.